JOURNAL FOR IMMUNOTHERAPY OF CANCER

JOURNAL FOR IMMUNOTHERAPY OF CANCER Journal

publication venue for

PHASE 2 TRIAL OF NEOADJUVANT AND ADJUVANT PD-1 CHECKPOINT BLOCKADE IN LOCAL-REGIONALLY ADVANCED, RESECTABLE HNSCC INDICATES PATHOLOGICAL RESPONSE IS ASSOCIATED WITH HIGH DISEASE-FREE SURVIVAL 2020

Electronic International Standard Serial Number (EISSN)

2051-1426